Frequency of Preterm Birth among Patients with Preeclampsia at a Tertiary Care Hospital
DOI:
https://doi.org/10.70749/ijbr.v3i6.2275Keywords:
Preeclampsia, Preterm birth, Hypertensive disorders of pregnancy, Maternal outcomes, Neonatal outcomes, Pakistan.Abstract
Background: Preterm birth is a leading cause of neonatal morbidity and mortality worldwide, with particularly high rates in South Asia. Preeclampsia significantly increases the risk of medically indicated preterm delivery, yet local data remain limited. Objective: To determine the frequency of preterm birth among women with preeclampsia at a tertiary care hospital in Pakistan and explore associated maternal and neonatal factors. Methodology: A descriptive cross-sectional study was conducted in the Department of Obstetrics & Gynaecology, PUMHS, Nawabshah, over six months, from September 2024 to March 2025. A total of 147 women aged 18–40 years, admitted with preeclampsia, were consecutively recruited after informed consent. Women with multiple gestations, chronic hypertension, gestational diabetes, or severe coexisting illnesses were excluded. Data on demographics, obstetric history, clinical parameters, and pregnancy outcomes were collected. Analysis was performed using SPSS 26, applying descriptive statistics, Chi-square, t-tests, and Mann–Whitney U tests, with p ≤0.05 as significant. Results: Preterm birth occurred in 51% of women with preeclampsia. Severe preeclampsia, earlier gestational age at diagnosis, heavier proteinuria, higher blood pressure, and obesity were significantly associated with preterm delivery. Preterm infants had markedly lower birth weights (1981 g vs. 3329 g) and were more often delivered by cesarean section (84% vs. 33%). Conclusion: Preeclampsia is strongly linked with high rates of preterm birth and adverse neonatal outcomes. Findings highlight the need for improved risk stratification, preventive interventions, and strengthening of antenatal care policies in resource-limited settings.
Downloads
References
pregnancy: novel insights into disease pathophysiology and clinical implications. Am J Obstet Gynecol. 2021;225(6):S122–S140.
https://www.ajog.org/article/S0002-9378(21)00723-2/fulltext
8. Xu X, Wang Y, Xu H, et al. Association between proteinuria and maternal and neonatal outcomes in pre-eclampsia pregnancy: a retrospective observational study. J Int Med Res. 2020;48(9):300060520908114.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7218474/ PMC
9. Lei T, Qiu T, Liao W, et al. Proteinuria may be an indicator of adverse pregnancy outcomes in patients with preeclampsia. Reprod Biol Endocrinol. 2021;19:71.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8120921/ PMC
10. Khan B, Allah Yar R, Khakwani AK, Karim S, Arslan Ali H. Preeclampsia incidence and its maternal and neonatal outcomes with associated risk factors. Cureus. 2022;14(11):e31143.
https://doi.org/10.7759/cureus.31143
11. Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders between 34 and 37 weeks (HYPITAT-II). Lancet. 2015;385(9986):2492–501.
https://doi.org/10.1016/s0140-6736(14)61998-x
12. Aune D, Saugstad OD, Henriksen T, Tonstad S. Maternal body mass index and the risk of preeclampsia: a systematic review and meta-analysis. Epidemiology. 2014;25(3):431–442.
https://doi.org/10.1097/ede.0000000000000036
13. Abraham TM, Zief S, Lara Mendivil E, et al. The relationship between obesity and preeclampsia: a review. Medicina (Kaunas). 2022;58(5):607.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9101603/ PMC
14. Yung HW, Colleoni F, Dommett E, Cindrova-Davies T, Kingdom J, Murray AJ, et al. Noncanonical mitochondrial unfolded protein response impairs placental oxidative phosphorylation in early-onset preeclampsia. Proceedings Nat Acad Sci US Am. 2019; 116(36):18109-18.
https://doi.org/10.1073/pnas.1907548116
15. World Health Organization. WHO recommendation: calcium supplementation during pregnancy for prevention of pre-eclampsia and its complications. Geneva: WHO; 2018.
https://apps.who.int/iris/handle/10665/277235
16. Staff AC, Redman CWG, Williams D, et al. Preeclampsia. Nat Rev Dis Primers. 2023;9:38.
https://www.nature.com/articles/s41572-023-00450-5 Taylor & Francis Online
17. American College of Obstetricians and Gynecologists. Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection (Committee Opinion No. 455, reaffirmed).
18. Rayes B, Karam N, Virani S, et al. Association of hypertensive disorders of pregnancy with long-term cardiovascular risk. JAMA Netw Open. 2023;6(3):e231027.
https://doi.org/10.1001/jamanetworkopen.2023.0034
19. Dong X, Yang M, Zhang G, et al. Proteinuria in preeclampsia: not essential to diagnosis but related to disease severity. Pregnancy Hypertens. 2017;10:70–75.
https://doi.org/10.1016/j.preghy.2017.03.005
20. Broekhuijsen K, van Baaren GJ, van Pampus MG, Ganzevoort W, Sikkema JM, Woiski MD, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT II): an open label, randomised controlled trial. Lancet. 2015;385(9986):2492 501.
https://doi.org/10.1016/S0140-6736(14)61998-X
21. Campbell OMR, Calvert C, Testa A, Strehlow M, Benova L, Keyes E, et al. The scale, scope, coverage, and capability of childbirth care. Lancet. 2016;388(10056):2193 208.
https://doi.org/10.1016/S0140-6736(16)31528-8
22. McDonald SD, Han Z, Mulla S, Beyene J, Knowledge Synthesis Group. Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta analyses. Lancet. 2010;375(9731): 2034 42.
https://doi.org/10.1016/S0140-6736(10)60750-9
23. World Health Organization. WHO recommendations for prevention and treatment of pre eclampsia and eclampsia. Geneva: World Health Organization; 2011.
https://www.who.int/publications/i/item/9789241548335
24. U.S. Preventive Services Task Force. Aspirin use to prevent preeclampsia and related morbidity and mortality: preventive medication. JAMA. 2021;326(12):1186 91.
https://doi.org/10.1001/jama.2021.14781
25. American College of Obstetricians and Gynecologists; Society for Maternal Fetal Medicine. Low dose aspirin use for the prevention of preeclampsia and related morbidity and mortality. ACOG Practice Advisory. 2021 Dec (reaffirmed 2022).
26. World Health Organization. WHO recommendation: calcium supplementation during pregnancy for prevention of pre eclampsia and its complications. Geneva: World Health Organization; 2018.
https://www.who.int/publications/i/item/9789241550451
27. Klemm GC, Birhanu Z, Ortolano SE, Kebede Y, Martin SL, Mamo G, et al. Integrating calcium into antenatal iron–folic acid supplementation in Ethiopia: women’s experiences, perceptions of acceptability, and strategies to support calcium supplement adherence. Glob Health Sci Pract. 2020;8(3):413 30.
https://doi.org/10.9745/GHSP-D-20-00008
28. WHO recommendations on interventions to improve preterm birth outcomes. Geneva: World Health Organization; 2015.
https://www.ncbi.nlm.nih.gov/books/NBK321160/
29. McDonald SD, Han Z, Mulla S, Beyene J, Knowledge Synthesis Group. Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta analyses. Lancet. 2010;375(9731):2034 42.
https://doi.org/10.1016/S0140-6736(10)60750-9
30. Yee LM, Miller EC, Greenland P. Mitigating the long-term health risks of adverse pregnancy outcomes. JAMA. 2022;327(5):411 2.
https://doi.org/10.1001/jama.2021.23870
31. US Preventive Services Task Force. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Recommendation Statement. JAMA. 2021;326(12):1186–1191.
https://doi.org/10.1001/jama.2021.14781
32. World Health Organization. WHO recommendations on antenatal corticosteroids for improving preterm birth outcomes. Geneva: WHO; 2022.
https://www.who.int/publications/i/item/9789240045880 PubMed
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
